Latest News Archive

Please select Category, Year, and then Month to display items

‘I wanted my family to be proud of me’, says BML graduate

08 December 2023 | Story Leonie Bolleurs | Photo Charl Devenish

Thabo Dithebe received his Bachelor of Management Leadership (BML) qualification during the University of the Free State’s December graduation ceremonies. His life journey of resilience, adaptability, and a willingness to embrace unexpected opportunities is an inspiring story that needs to be told.

Born in the farming community of Bothaville, Thabo initially wanted to pursue a career in engineering, and he chose maths, science, and technical subjects in high school. However, a temporary job in retail near home and experiencing the toll of retrenchment redirected his path to sales and marketing and pushed him to apply for a BML in the UFS Business School.

“When I enrolled for the BML, my childhood dream of going to university became a reality. Although the journey was not easy, it was worth pursuing,” says Thabo, who is employed as an area sales manager at Marltons Pet Care.

Balancing studies and responsibilities at home

In addition to managing the pressure of being stretched to the limit in class, Thabo also had to balance his studies with the responsibilities at home – taking care of his sick and disabled daughter.

“Balancing these commitments was always a challenge, but I was fortunate to have a supportive caregiver who understood the needs of children living with disabilities. There were tough times, especially during submission seasons when my daughter would fall ill. In those moments, I had to prioritise her health, temporarily setting aside my studies until she received proper care at the hospital,” he states.

Besides caring for his daughter and being retrenched, he also went through a breakup. Thabo believes that things could have turned out differently if he had stopped imagining and dreaming, because he had every reason to give up. He describes reaching this significant milestone in his life as ‘unreal’.

He says that he was motivated to persevere, because from the first day he enrolled, he wanted to make his family proud of him. “There were times when I asked myself if I had what it takes to complete the programme. Should I choose not to complete the course, what would I say to my son when life knocks him down, when he sees me giving up? How do I face my mother if I came back defeated? I had good people on my side who wanted me to succeed,” he says.

Ready to take on the next challenge

Having reached this significant milestone in his life, Thabo is ready for the next challenge. “I am hoping to be accepted into the PGDip in Business Administration programme for the 2024 intake,” he says.

He advises others who face challenges while pursuing their educational goals to understand that their situation is not permanent and that there is strength in adversity. “It is important to celebrate the small victories often and to associate yourself with people who work harder than you,” he adds.

On 7 December 2023, as Thabo walked across the stage, he looked for the face of his mother in the audience – a lady who made several sacrifices to raise him and his five siblings. “I hope that when she saw me, she was very proud of me,” he concludes.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept